Abstract
Summary
We determined hypovitaminosis D prevalence in men with psoriatic arthritis. This is a cross-sectional, analyst blinded, age- and sex-matched, case-control study. Men with psoriatic arthritis have significantly lower 25-hydroxyvitamin D levels. Men with psoriatic arthritis are at increased odds of suffering from hypovitaminosis D.
Introduction
Skeletal manifestations as a result of abrupted bone metabolism may be predominant in psoriatic arthritis (PsA). Vitamin D plays a vital role in maintenance of skeletal health and is known to modulate the immune system in various autoimmune diseases including PsA. The aim of the present study was to determine the prevalence of hypovitaminosis D in a treatment naïve, de novo psoriatic arthritis male cohort in a cross-sectional, analyst blinded, age- and sex-matched, case-control study.
Methods
25 hydroxyvitamin D (25OHD), parathyroid (PTH), osteocalcin (OC) and C-terminal telopeptides of type-I collagen (CTx) levels, and lumbar spine and femoral neck bone mineral density were compared between 53 PsA and controls.
Results
The prevalence of hypovitaminosis D (25 hydroxyvitamin D (25OHD) levels <75 nmol/L) was 81 and 57 % in the PsA and control groups, respectively. Compared to the healthy controls, 25OHD (67.2 (12–137) nmol/L vs. 51.9 (15–95) nmol/L; p = 0.001) was significantly lower, and osteocalcin (13.6 (5–33) μg/L vs. 18.2 (6–35) μg/L; p = 0.003) and C-terminal telopeptides of type-I collagen (0.20 (0.01–0.71) μg/L vs. 0.28 (0.06–0.69) μg/L; p = 0.008) were significantly higher in the PsA group. A significant association was found between hypovitaminosis D and PsA; the odds for patients with PsA of having hypovitaminosis D was 3.297 (95 % confidence interval 1.372 to 7.922).
Conclusion
The results of this study suggest that men with PsA have significantly lower 25-hydroxyvitamin D levels, and furthermore, men with PsA are at statistically significant increased odds of suffering from hypovitaminosis D.
Similar content being viewed by others
References
Myers WA, Gottlieb AB, Mease P (2006) Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol 24:438–447
Leonard DG, O’Duffy JD, Rogers RS (1978) Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc 53:511–508
Shbeeb M, Uramoto KM, Gibson LE, O’Fallon WM, Gabriel SE (2000) The epidemiology of psoriatic arthritis in Olmstead County, Minnesota, USA, 1982–1991. J Rheumatol 27:1247–1250
Henseler T, Christophers E (1985) Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 13:450–456
Ferrandiz C, Pujol RM, Garcia-Patos V, Bordas X, Smandia JA (2002) Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol 46:867–873
McHugh NJ, Balachrishnan C, Jones SM (2003) Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) 42:778–783
Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, Stern RS, Feldman SR, Rolstad T (2005) Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 53:573
Gladman D, Antoni C, Mease P, Clegg DO, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64:ii14–ii17
Mease PJ, Goffe BS (2005) Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 52:1–19
Omdahl JL, Garry PJ, Hunsaker LA, Hunt WC, Goodwin JS (1982) Nutritional status in a healthy elderly population: vitamin D. Am J Clin Nutr 36:1225–1233
Khaw KT, Sneyd MJ, Compston J (1992) Bone density parathyroid hormone and 25-hydroxyvitamin D concentrations in middle aged women. BMJ 305:273–277
Ooms ME, Lips P, Roos JC, van der Vijgh WJ, Popp-Snijders C, Bezemer PD, Bouter LM (1995) Vitamin D status and sex hormone binding globulin: determinants of bone turnover and bone mineral density in elderly women. J Bone Miner Res 10:1177–1784
McAuley KA, Jones S, Lewis-Barned NJ, Manning P, Goulding A (1997) Low vitamin D status is common among elderly Dunedin women. N Z Med J 110:275–277
Stumpf WE, Sar M, Clark SA, DeLuca HF (1982) Brain target sites for 1,25-dihydroxyvitamin D3. Science 215:1403–1405
Clemens TL, Garrett KP, Zhou XY, Pike JW, Haussler MR, Dempster DW (1988) Immunocytochemical localization of the 1,25-dihydroxyvitamin-D3 receptor in target cells. Endocrinology 122:1224–1230
Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, Dominguez CE, Jurutka PW (1998) The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13:325–349
Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM, Hewison M (2001) Extrarenal expression of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 86:888–894
Bhalla AK, Amento EP, Clemens TL, Holick MF, Krane SM (1983) Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab 57:1308–1310
Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC (1983) 1,25-Dihydroxyvitamin D3 receptors in human leukocytes. Science 221:1181–1183
Huckins D, Felson DT, Holick M (1990) Treatment of psoriatic arthritis with oral 1,25-dihydroxyvitamin D3: a pilot study. Arthritis Rheum 33:1723–1727
Dubertret L, Wallach D, Souteyrand P, Perussel M, Kalis B, Meynadier J, Chevrant-Breton J, Beylot C, Bazex JA, Jurgensen HJ (1992) Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris: a randomized, double-blind, right/left comparative, vehicle-controlled study. J Am Acad Dermatol 27:983–988
Nagpal S, Na S, Rathnachalam R (2005) Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 26:662–687
Nieves J, Nieves J, Cosman F, Herbert J, Shen V, Lindsay R (1994) High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 44:1687–1692
Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG (2004) Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa women’s health study. Arthritis Rheum 50:72–77
Devaraj S, Yun JM, Duncan-Staley CR, Jialal I (2011) Low vitamin D levels correlate with the proinflammatory state in type 1 diabetic subjects with and without microvascular complications. Am J Clin Pathol 135:429–433
Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R (2005) Estimates of optimal vitamin D status. Osteoporos Int 16:713–716
Fredriksson T, Pettersson U (1978) Severe psoriasis—oral therapy with a new retinoid. Dermatologica 157:238–244
Prevoo ML, Van’t Hof MA, Kuper HH, Van Leeuwen MA, Van de Putte LB, Van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48
Bhattoa HP, Nagy E, More C, Kappelmayer J, Balogh A, Kalina E, Antal-Szalmas P (2013) Prevalence and seasonal variation of hypovitaminosis D and its relationship to bone metabolism in healthy Hungarian men over 50 years of age. The HunMen study. Osteoporos Int 24:179–186
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673
Orgaz-Molina J, Buendía-Eisman CA, Arrabal-Polo MA, Ruiz JC, Arias-Santiago S (2012) Deficiency of serum concentration of 25-hydroxyvitamin D in psoriatic patients: a case-control study. J Am Acad Dermatol 67:931–938
Orgaz-Molina J, Magro-Checa C, Rosales-Alexander JL, Arrabal-Polo MA, Buendía-Eisman A, Raya-Alvarez E, Arias-Santiago S (2013) Association of 25-hydroxyvitamin D serum levels and metabolic parameters in psoriatic patients with and without arthritis. J Am Acad Dermatol 69:938–946
Del Puente A, Esposito A, Parisi A, Atteno M, Montalbano S, Vitiello M, Esposito C, Bertolini N, Foglia F, Costa L, Scarpa R (2012) Osteoporosis and psoriatic arthritis. J Rheumatol 89:36–38
Borman P, Babaoglu S, Gur G, Bingol S, Bodur H (2008) Bone mineral density and bone turnover in patients with psoriatic arthritis. Clin Rheumatol 27:443–447
Attia EA, Khafagy A, Abdel-Raheem S, Fathi S, Saad AA (2011) Assessment of osteoporosis in psoriasis with and without arthritis: correlation with disease severity. Int J Dermatol 50:30–35
Frediani B, Allegri A, Falsetti P, Storri L, Bisogno S, Baldi F, Filipponi P, Marcolongo R (2001) Bone mineral density in patients with psoriatic arthritis. J Rheumatol 28:138–143
Pedreira PG, Pinheiro MM, Szejnfeld VL (2011) Bone mineral density and body composition in postmenopausal women with psoriasis and psoriatic arthritis. Arthritis Res Ther 13:R16
Holick MF (1994) Vitamin D—new horizons for the 21st century. Am J Clin Nutr 60:619–630
Acknowledgments
This work is supported by the Hungarian Scientific Research Fund (OTKA) 105073 research grant (H.P.B.).
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Petho, Z., Kulcsar-Jakab, E., Kalina, E. et al. Vitamin D status in men with psoriatic arthritis: a case-control study. Osteoporos Int 26, 1965–1970 (2015). https://doi.org/10.1007/s00198-015-3069-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-015-3069-2